Frova news from FierceBiotech
NewsVernalis inks financing deal
Vernalis has signed a €18.4M financing agreement with Paul Capital Healthcare for frovatriptan, Vernalis' migraine drug. In return for the cash, Paul Capital Healthcare will receive Read more...
Endo pulls Frova app after mulling FDA response
Endo Pharmaceuticals says a close reading of a non-approvable letter from the FDA for Frova prompted officials to pull their request to gain approval for the short-term relief of menstrual migraine. Read more...
Vernalis may be in play after dramatic reorg
The UK's Vernalis saw its shares shoot up after the drug developer announced a dramatic restructuring that will eliminate more than half of its work force and put significant parts of its business up Read more...
Endo touts successful Phase III in cancer pain
Endo Therapeutics' late-stage trial for Rapinyl, a cancer pain therapy, demonstrated that the therapy was highly effective, hitting all primary and secondary goals. The biotech said the trial was so Read more...
Endo, Vernalis get FDA rejection for Frova
Endo Pharmaceuticals and Vernalis have received a "not approvable" letter for an additional indication for its migraine medicine Frova. The companies had hoped to gain an approval for menstrual Read more...
| Press ReleasesPRESS RELEASE: FDA Informs Endo and Vernalis That New Target Action Date on Frova sNDA Is Sept. 30, 2007 FDA Informs Endo and Vernalis That New Target Action Date on Frova sNDA Is Sept. 30, 2007 CHADDS FORD, PA and WINNERISH, UK, Sep 10, 2007 -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight